久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
World
Home / World / Europe

BioNTech revenues boosted by COVID-19 vaccine programs

Xinhua | Updated: 2020-11-11 05:13
Share
Share - WeChat
Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. [Photo/Agencies]

BERLIN, Nov. 10 (Xinhua) -- German pharmaceutical company BioNTech SE announced on Tuesday that its revenues climbed to 136.9 million euros (161.7 million U.S. dollars) in the first nine months of the year, compared with 80.6 million euros in the same period last year.

The development of revenues was driven by new collaborations with U.S. company Pfizer and China's Fosun Pharma within the BNT162 vaccine program against COVID-19, according to the German company.

"We have initiated the first rolling regulatory submission processes for our COVID-19 vaccine program in the EU (European Union), the UK and Canada and we are continuing to work with our partners to scale-up production capacity to prepare for a potential global launch of our COVID-19 vaccine, if approved," said Ugur Sahin, chief executive officer (CEO) of BioNTech, in a statement.

In August, BioNTech and China's Fosun Group already started a Phase 1 study to evaluate safety and immunogenicity of the vaccine candidate in Chinese participants. BioNTech is expecting to start a Phase 2 clinical trial in China by the end of the year, once regulatory approval from China's National Medical Products Administration (NMPA) was granted.

On Monday, BioNTech and Pfizer announced that their vaccine candidate showed more than 90 percent efficacy in protecting against COVID-19 in volunteers with no proven previous SARS-CoV-2 infection.

Furthermore, no serious side effects had been observed based on first interim results from the ongoing Phase 3 clinical study conducted by an external, independent Data Monitoring Committee (DMC), according to a joint statement by the companies.

"Yesterday's announcement regarding the first interim analysis from our global Phase 3 trial for our COVID-19 vaccine candidate, BNT162, is a watershed moment for both our company and scientific innovation," stressed Sahin.

BioNTech and Pfizer are planning to submit their potential COVID-19 vaccine candidate for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) in the third week of November.

For the development of a COVID-19 vaccine, BioNTech received 375 million euros from a special vaccine development program by the German government. The progress made by BioNTech and Pfizer was "very encouraging," German Minister of Health Jens Spahn said during a press conference on Monday.

Spahn emphasized that the European Commission had the mandate to negotiate with pharmaceutical companies at the European level. In a statement issued on Tuesday, the Commission said it will authorize on Wednesday a contract for up to 300 million doses of the vaccine developed by BioNTech and Pfizer.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 成年免费观看 | 亚洲美女在线观看亚洲美女 | 国产精品日韩欧美在线第3页 | 深夜爽爽爽gif福利免费 | 中文精品视频一区二区在线观看 | 五月色婷婷琪琪综合伊人 | 日韩欧美亚洲中字幕在线播放 | fc2ppv在线观看| 亚洲精品成人7777在线观看 | 91久久精品一区二区三区 | 偷拍亚洲欧美 | 国产伦精品一区二区三区网站 | 日本无卡码免费一区二区三区 | 美国三级毛片 | 中文字幕亚洲一区 | 国产aⅴ精品一区二区三区久久 | 99视频在线免费 | 中文字幕免费视频 | 99re热久久| 亚洲成人高清在线观看 | 成在线人免费视频 | 尹人在线视频 | 毛片视频网址 | 欧美日韩一区二区三区视频 | 黄色毛片子 | 久久精品最新免费国产成人 | 免费一级夫妻a | 夜色www国产精品资源站 | 国产成人啪精品视频免费软件 | 99在线观看视频免费精品9 | 中文国产成人精品久久久 | 欧美大片在线播放 | 女人一级特纯黄大片色 | 亚洲精品手机在线观看 | 爱爱毛片 | 国产精品久久久久久久午夜片 | 深夜做爰性大片中文 | 久久欧美久久欧美精品 | 国产综合亚洲专区在线 | 在线精品播放 | 国产在视频线在精品 |